Business Context and Reporting Period
This Form 8-K Current Report was filed by Synta Pharmaceuticals Corp. on August 6, 2014, reporting events occurring on August 1, 2014. The filing addresses the appointment of a new Chief Executive Officer and President, replacing an interim executive committee.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
- Base Salary: $550,000 per year.
- Target Annual Bonus: 60% of base salary ($330,000).
- Sign-on Bonus: $270,000 (with $135,000 clawback provision if resigned without Good Reason within one year).
- Relocation Allowance: $85,000 miscellaneous allowance plus reimbursement of reasonable costs.
- Equity Grants: Options to purchase 750,000 shares and 500,000 shares of restricted common stock.
Material Changes
The primary material change is the leadership transition effective September 2, 2014:
- Appointment: Anne C. Whitaker appointed as CEO, President, and Board Director.
- Departure: The interim Executive Committee (Keith R. Gollust, Robert N. Wilson, Paul A. Friedman) is dissolved.
- Role Change: Keith R. Gollust ceases to serve as Executive Chairman but remains Chairman of the Board.
Outlook, Risks, and Unusual Items
Management Commentary: Ms. Whitaker brings over 20 years of healthcare experience, including leading North America Pharmaceuticals at Sanofi Aventis and senior roles at GlaxoSmithKline.
Compensation Risks and Contingencies:
- Severance (Termination without Cause/Good Reason): 18 months salary continuation, acceleration of equity vesting for 18 months, and 18 months of health insurance costs.
- Change of Control Severance: If terminated within 90 days prior to or one year after a Change of Control, the package increases to 24 months salary, pro-rated bonus, full equity acceleration, and 24 months of health insurance costs.
- Restrictions: A 12-month non-competition and non-solicitation agreement applies post-employment.
Investor Verification Checklist
- Verify the commencement date of September 2, 2014, for the new CEO.
- Confirm the vesting schedule for the 750,000 stock options and 500,000 restricted shares (25% at one year, then quarterly).
- Review the definition of "Good Reason" and "Cause" in the attached Executive Employment Agreement (Exhibit 10.1).
- Assess the impact of the $270,000 sign-on bonus and $85,000 allowance on immediate cash flow.
- Monitor the dissolution of the interim Executive Committee and the transition of duties.